0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > B7-1

B7-1

B7-1 Molecule Information

Name:Cluster of Differentiation 80
Target Synonym:CD80;LAB7;B7;T-lymphocyte activation antigen CD80;CD_antigen=CD80;CTLA-4 counter-receptor B7.1;CD28LG1;CD28LG ;Activation B7-1 antigen;BB1
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:14
Lastest Research Phase:Approved

B7-1 Protein Product ListCompare or Buy

B7-1 Molecule Synonym Name

CD80,B7,B7-1,B7.1,BB1,CD28LG,CD28LG1,LAB7

B7-1 Molecule Background

B7-1 and B7-2, together with their receptors CD28 and CTLA­4, constitute one of the dominant co-stimulatory pathways that regulate T­ and B­cell responses. Although both CTLA­4 and CD28 can bind to the same ligands, CTLA­4 binds to B7­1 and B7­2 with a 20 ­ 100 fold higher affinity than CD28 and is involved in the down­regulation of the immune response. B-lymphocyte activation antigen B7-1 (referred to as B7) also known as cluster of Differentiation 80 (CD80), is a member of cell surface immunoglobulin superfamily and is expressed on activated B cells, activated T cells, macrophages and dendritic cells. It is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD80 works in tandem with CD86 to prime T cells. CD80 plays a role in induction of innate immune responses by activating NF-?B-signaling pathway in macrophages. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.

B7-1 Related Molecule

B7-1 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Belatacept BMS-224818; LEA29Y; L104EA29YIg; LEA-029 Approved Bristol-Myers Squibb NULOJIX fda Rejection of organ transplantation BRISTOL MYERS SQUIBB 2011-06-15 Rejection of organ transplantation, Rejection of renal transplantation Details
Abatacept BMS-188667; ONO-4164; BMS-188667SC; ONO-4164SC,MS188667; ONO4164; BMS188667SC; ONO4164SC Approved Bristol-Myers Squibb, Ono Pharmaceutical ORENCIA fda Rheumatoid arthritis (RA), Juvenile rheumatoid arthritis (JRA) BRISTOL MYERS SQUIBB 2005-12-23 Juvenile idiopathic arthritis (JIA), Psoriatic arthritis, Rheumatoid arthritis (RA), Juvenile rheumatoid arthritis (JRA) Details

B7-1 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Belatacept biosimilar (Alphamab) KN-019 Phase Ⅱ Alphamab Autoimmune diseases, Rejection of renal transplantation Details
Abatacept biosimilar (Momenta Pharmaceuticals) M-834 Phase Ⅰ Momenta, Mylan Autoimmune diseases, Immune-inflammatory diseases Details
Recombinant canarypox virus-based vaccine (Sanofi Pasteur) ALVAC-CEA/B7.1 Phase Ⅱ Sanofi Pasteur, Therion Biologics Colorectal cancer, Melanoma Details
RG 2077 Phase Ⅰ Repligen Diabetes, Graft versus host disease, Systemic lupus erythematosus, Multiple sclerosis (MS), Rheumatoid arthritis (RA), Idiopathic thrombocytopenic purpura (ITP) Details
Abatacept biosimilar (Hanwha Biologics) Phase Not Specified Hanwha Biologics Arthritis Details
Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) Z-CTLs Phase Ⅰ Hunan Zhaotai Yongren Biotech Non small cell lung cancer (NSCLC) Details
Recombinant human CTLA4-Ig Fusion protein(Shanghai CP Guojian) Phase Ⅰ Shanghai CP Guojian Rheumatoid arthritis (RA) Details
Galiximab IDEC-114; IDEC-114-20; Anti-B7.1-MAb Phase Ⅱ Biogen Lymphoma Details
B7-1 cancer vaccine Phase Ⅰ Nonindustrial source, Kings College London, National Cancer Institute Acute myeloid Leukemia (AML), Ovarian cancer, Pancreatic cancer Details
Humanized anti-B7 antibodies (Pfizer) Phase Ⅱ Pfizer Graft versus host disease, Transplant rejection Details
rVV-740CTA vaccine (University Hospital Basel) rVV-740CTA,rVV 740CTA Phase Ⅰ University Hospital Basel Breast cancer Details
AV-1142742 AV-1142742 Phase Ⅱ Active Biotech, MediGene AG Autoimmune diseases Details
ASP-2408 ASP-2408 Phase Ⅰ Maxygen, Astellas Rheumatoid arthritis (RA) Details
CTLA-4/FasL fusion protein (KAHR Medical) KAHR-102 IND Filing KAHR Medical Lymphoma Details

This web search service is supported by Google Inc.

totop